Litigation of unlicensed US stem cell products
Authors:
- 1 May 2025
- journal article
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (5) , 684-688
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventionsCell Stem Cell, 2021
- Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood–Derived Products Marketed as Stem Cell TherapiesJAMA Network Open, 2021
- Online Direct-to-Consumer Advertising of Stem Cell Therapy for Musculoskeletal Injury and DiseaseJournal of Bone and Joint Surgery, 2019
- Stem cell therapy as an adjunct to surgeryInternational Journal of Surgery, 2019
- Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based InterventionsStem Cells Translational Medicine, 2018
- Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventionsnpj Regenerative Medicine, 2018
- Selling Stem Cells in the USA: Assessing the Direct-to-Consumer IndustryCell Stem Cell, 2016
- Medicine's Wild West — Unlicensed Stem-Cell Clinics in the United StatesNew England Journal of Medicine, 2015
- Stem cell tourism – A web-based analysis of clinical services available to international travellersTravel Medicine and Infectious Disease, 2014